NASDAQ: NUVL - Nuvalent, Inc.

Yield per half year: -9.5%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Nuvalent, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Nuvalent, Inc.

Nuvalent, Inc., биофармацевтическая компания, работающая на доклинической стадии, разрабатывает методы лечения онкологических больных.

more details
Его ведущими кандидатами в продукт являются NVL-520, проникающий в мозг ROS1-селективный ингибитор, разработанный для ингибирования слияний ROS1, которые экспрессируют нормальный домен киназы ROS1 без каких-либо устойчивых к лекарствам мутаций, а также остаются активными в присутствии мутаций, придающих устойчивость к одобренным и исследуемые ингибиторы ROS1; и NVL-655, проникающий в мозг ALK-селективный ингибитор, разработанный для ингибирования слияний ALK, которые экспрессируют нормальный домен киназы ALK без каких-либо устойчивых к лекарствам мутаций, а также остаются активными в присутствии мутаций, придающих устойчивость к первому, второму и третьему поколение ингибиторов ALK. Компания была зарегистрирована в 2017 году, ее штаб-квартира находится в Кембридже, Массачусетс.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-07-29
ISIN US6707031075
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.nuvalent.com
Цена ао 75.89
Change price per day: +1.52% (75.89)
Change price per week: -6.49% (82.39)
Change price per month: -9.74% (85.35)
Change price per 3 month: -20.38% (96.76)
Change price per half year: -9.5% (85.13)
Change price per year: -8.42% (84.12)
Change price per 3 year: +382.1% (15.98)
Change price per 5 year: 0% (77.04)
Change price per 10 year: 0% (77.04)
Change price per year to date: -7.68% (83.45)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 6.18 1
P/E 0 0
EV/EBITDA -26.69 0
Total: 1.25

Efficiency

Title Value Grade
ROA, % -17.23 0
ROE, % -18.02 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.015 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 1113.64 10
Yield EPS, % 196.96 10
Total: 8
More

Institutions Volume Share, %
Deerfield Management Company, L.P. (Series C) 20 33.81
FMR, LLC 9 14.88
Paradigm Biocapital Advisors LP 4 7.07
Vanguard Group Inc 3 5.77
Perceptive Advisors LLC 3 4.71
Blackrock Inc. 3 4.58
Bain Capital Life Sciences Investors, LLC 3 4.56
Fairmount Funds Management LLC 2 3.26
State Street Corporation 2 2.56
COMMODORE CAPITAL LP 1 2.52

ETF Share, % Profitability for 1 year, % Dividends, %
Global X Guru Index ETF 2.13203 38.91 0.71623
Renaissance IPO ETF 1.68409 35.75 0.35581
Range Cancer Therapeutics ETF 1.66072 47.24 0.11955
Virtus LifeSci Biotech Clinical Trials ETF 1.08114 63.04 0.33
Future Tech ETF 0.61946 426.34 0.8416
Principal Healthcare Innovators ETF 0.61946 618.5 0.8416
First Trust US Equity Opportunities ETF 0.61156 39.99 0.69524
Invesco Nasdaq Biotechnology ETF 0.588 28.58 0.8565
First Trust Nasdaq Pharmaceuticals ETF 0.57702 18.37 2.19901
Direxion Daily S&P Biotech Bull 3x Shares 0.55954 4067.92 0.25924
First Trust Multi-Manager Small Cap Opportunities ETF 0.50646 48.51 0.31756
ProShares Ultra Nasdaq Biotechnology 0.40318 51.7 0.85651
John Hancock Multifactor Small Cap ETF 0.28834 16.88 1.54912
iShares Russell 2000 Growth ETF 0.2767 38.04 0.6026
JPMorgan BetaBuilders U.S. Small Cap Equity Fund 0.20506 24.75 1.59225
Vanguard Russell 2000 Growth ETF 0.2 23.05 0.60264
Vanguard U.S. Momentum Factor ETF 0.14 30.05 1.05834
iShares Morningstar Small-Cap Growth ETF 0.13985 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.13985 587.89 0.72598
Fidelity Growth Opportunities ETF 0.12628 32.75 0.48881
BNY Mellon US Small Cap Core Equity ETF 0.12128 30.07 1.75333
Vanguard Small Cap Value ETF 0.1 17.27 2.19419
Vanguard Russell 2000 ETF 0.1 17.16 1.48801
Schwab U.S. Small-Cap ETF 0.0998 17.47 1.51433
ProShares UltraPro Russell2000 0.07452 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.07013 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.07013 391.25 1.60498
iShares ESG Aware MSCI USA Small-Cap ETF 0.06801 18.09 1.49366
Fidelity MSCI Health Care Index ETF 0.04963 3 1.46057
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.04481 31.36 1.41955
Humankind US Stock ETF 0.02787 18.81 1.99919
ProShares Hedge Replication ETF 0.01995 5.92 1.47892
Dimensional U.S. Core Equity 2 ETF 0.01123 30.76 1.47098
Vanguard ESG U.S. Stock ETF 0.01 23.54 1.26927
Dimensional US Core Equity Market ETF 0.00891 30.98 1.40618
Schwab U.S. Broad Market ETF 0.00709 24.86 1.43354
iShares Russell 3000 ETF 0.00692 24.83 1.43482
Dimensional U.S. Equity ETF 0.00435 31.53 1.3557
SPDR Portfolio MSCI Global Stock Market ETF 0.00419 17.99 2.19607
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Dr. James R. Porter Ph.D. CEO, President & Director 998.02k 1976 (49 years)
Prof. Matthew D. Shair Ph.D. Founder, Head of Scientific Advisory Board & Director 235k 1969 (56 years)
Ms. Deborah Ann Miller J.D., Ph.D. Chief Legal Officer & Secretary 595.96k 1976 (49 years)
Ms. Darlene Noci Chief Development Officer N/A 1978 (47 years)
Dr. Christopher D. Turner M.D. Chief Medical Officer 714.26k 1969 (56 years)
Mr. Matthew Metivier Senior Vice President of Human Resources N/A
Mr. Henry Pelish Ph.D. Chief Scientific Officer N/A
Mr. John Soglia Ph.D. Senior Vice President of Translational Development N/A
Dr. Benjamin Lane Ph.D. Senior Vice President of Technical Operations N/A
Ms. Alexandra Balcom CPA, M.B.A. CFO & Treasurer 1985 (40 years)

Address: United States, Cambridge. MA, One Broadway - open in Google maps, open in Yandex maps
Website: https://www.nuvalent.com